繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

GRI Bio报告第一季度业绩

2026-05-15 02:31

  • GRI Bio press release (GRI): Q1 Net loss for the quarter ended March 31, 2026, was approximately $2.0 million, compared to approximately $3.0 million for the same period in 2025
  • Cash and cash equivalents totaled approximately $11.0 million as of March 31, 2026, compared to approximately $8.2 million as of December 31, 2025..

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。